Updated study data set for November symposium presentation
Perspective Therapeutics flagged updated data from its [212Pb]VMT-α-NET study for presentation at the EORTC-NCI-AACR Symposium in November 2026.
Interim results were already presented at the 2026 ASCO meeting, based on an April 17, 2026 data cut-off.
The program showed early signs of clinical activity with an initial safety profile in advanced SSTR2-positive neuroendocrine tumors, without prior radiopharmaceutical therapy.
The trial remains ongoing as a multi-center, open-label dose-escalation and dose-expansion study in unresectable or metastatic disease.
Additional readouts are expected as enrollment progresses, including pending efficacy updates from later cohorts in 2026 and 2027.
CATX•
